{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T19:45:57Z","timestamp":1793562357640,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T00:00:00Z","timestamp":1551052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00198-019-04906-x","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T10:30:45Z","timestamp":1551090645000},"page":"1145-1156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":166,"title":["Glucocorticoid-induced osteoporosis: 2019 concise clinical review"],"prefix":"10.1007","volume":"30","author":[{"given":"G.","family":"Adami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-8078","authenticated-orcid":false,"given":"K. G.","family":"Saag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,25]]},"reference":[{"key":"4906_CR1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/acr.21796","volume":"65","author":"RA Overman","year":"2013","unstructured":"Overman RA, Yeh J-Y, Deal CL (2013) Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken) 65:294\u2013298. \n                    https:\/\/doi.org\/10.1002\/acr.21796","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4906_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/bmj.313.7053.344","volume":"313","author":"LJ Walsh","year":"1996","unstructured":"Walsh LJ, Wong CA, Pringle M, Tattersfield AE (1996) Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313:344\u2013346. \n                    https:\/\/doi.org\/10.1136\/bmj.313.7053.344","journal-title":"BMJ"},{"key":"4906_CR3","first-page":"1298","volume":"28","author":"A Mudano","year":"2001","unstructured":"Mudano A, Allison J, Hill J et al (2001) Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol 28:1298\u20131305","journal-title":"J Rheumatol"},{"key":"4906_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","volume":"96","author":"KG Saag","year":"1994","unstructured":"Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96:115\u2013123. \n                    https:\/\/doi.org\/10.1016\/0002-9343(94)90131-7","journal-title":"Am J Med"},{"key":"4906_CR5","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s00198-015-3455-9","volume":"27","author":"MA Amiche","year":"2016","unstructured":"Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, L\u00e9vesque LE, Adachi JD, Cadarette SM (2016) Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int 27:1709\u20131718. \n                    https:\/\/doi.org\/10.1007\/s00198-015-3455-9","journal-title":"Osteoporos Int"},{"key":"4906_CR6","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00198-017-3976-5","volume":"28","author":"C Roux","year":"2017","unstructured":"Roux C, Briot K (2017) Imminent fracture risk. Osteoporos Int 28:1765\u20131769. \n                    https:\/\/doi.org\/10.1007\/s00198-017-3976-5","journal-title":"Osteoporos Int"},{"key":"4906_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11657-018-0424-x","volume":"13","author":"MA Amiche","year":"2018","unstructured":"Amiche MA, Abtahi S, Driessen JHM, Vestergaard P, de Vries F, Cadarette SM, Burden AM (2018) Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos 13:30. \n                    https:\/\/doi.org\/10.1007\/s11657-018-0424-x","journal-title":"Arch Osteoporos"},{"key":"4906_CR8","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1007\/s00198-016-3646-z","volume":"27","author":"A Balasubramanian","year":"2016","unstructured":"Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O\u2019Malley CD, Saag K, Curtis JR (2016) Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int 27:3239\u20133249. \n                    https:\/\/doi.org\/10.1007\/s00198-016-3646-z","journal-title":"Osteoporos Int"},{"key":"4906_CR9","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","volume":"39","author":"TP Staa van","year":"2000","unstructured":"van Staa TP, Leufkens HG, Abenhaim L et al (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383\u20131389. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/39.12.1383","journal-title":"Rheumatology (Oxford)"},{"key":"4906_CR10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Staa Van","year":"2000","unstructured":"Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993\u20131000. \n                    https:\/\/doi.org\/10.1359\/jbmr.2000.15.6.993","journal-title":"J Bone Miner Res"},{"key":"4906_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12916-017-0987-1","volume":"16","author":"Z Paskins","year":"2018","unstructured":"Paskins Z, Whittle R, Sultan AA, Muller S, Blagojevic-Bucknall M, Helliwell T, Hider S, Roddy E, Mallen C (2018) Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study. BMC Med 16:4. \n                    https:\/\/doi.org\/10.1186\/s12916-017-0987-1","journal-title":"BMC Med"},{"key":"4906_CR12","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00198-013-2587-z","volume":"25","author":"IEM Bultink","year":"2014","unstructured":"Bultink IEM, Harvey NC, Lalmohamed A, Cooper C, Lems WF, van Staa TP, de Vries F (2014) Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int 25:1275\u20131283. \n                    https:\/\/doi.org\/10.1007\/s00198-013-2587-z","journal-title":"Osteoporos Int"},{"key":"4906_CR13","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C","volume":"42","author":"R Ramsey-Goldman","year":"1999","unstructured":"Ramsey-Goldman R, Dunn JE, Huang CF, Dunlop D, Rairie JE, Fitzgerald S, Manzi S (1999) Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 42:882\u2013890. \n                    https:\/\/doi.org\/10.1002\/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C","journal-title":"Arthritis Rheum"},{"key":"4906_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jdiacomp.2016.06.021","volume":"31","author":"SS Casagrande","year":"2017","unstructured":"Casagrande SS, Cowie CC, Malozowski S (2017) Glucocorticoid use and its association with skeletal health among U.S. adults with diabetes. J Diabetes Complicat 31:353\u2013357. \n                    https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.06.021","journal-title":"J Diabetes Complicat"},{"key":"4906_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/jbmr.257","volume":"26","author":"L Graat-Verboom","year":"2011","unstructured":"Graat-Verboom L, van den Borne BEEM, Smeenk FWJM, Spruit MA, Wouters EFM (2011) Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J Bone Miner Res 26:561\u2013568. \n                    https:\/\/doi.org\/10.1002\/jbmr.257","journal-title":"J Bone Miner Res"},{"key":"4906_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00198-016-3732-2","volume":"28","author":"P-C Lu","year":"2017","unstructured":"Lu P-C, Yang Y-H, Guo S-E, Yang T-M (2017) Factors associated with osteoporosis in patients with chronic obstructive pulmonary disease-a nationwide retrospective study. Osteoporos Int 28:359\u2013367. \n                    https:\/\/doi.org\/10.1007\/s00198-016-3732-2","journal-title":"Osteoporos Int"},{"key":"4906_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.11005\/jbm.2016.23.3.111","volume":"23","author":"R Okazaki","year":"2016","unstructured":"Okazaki R, Watanabe R, Inoue D (2016) Osteoporosis associated with chronic obstructive pulmonary disease. J Bone Metab 23:111\u2013120. \n                    https:\/\/doi.org\/10.11005\/jbm.2016.23.3.111","journal-title":"J Bone Metab"},{"key":"4906_CR18","doi-asserted-by":"publisher","unstructured":"Jones A, Fay JK, Burr ML, Stone M, Hood K, Roberts G, Cochrane Airways Group (2002) Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev. \n                    https:\/\/doi.org\/10.1002\/14651858.CD003537","DOI":"10.1002\/14651858.CD003537"},{"key":"4906_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1164\/rccm.200305-640OC","volume":"169","author":"S Suissa","year":"2004","unstructured":"Suissa S, Baltzan M, Kremer R, Ernst P (2004) Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 169:83\u201388. \n                    https:\/\/doi.org\/10.1164\/rccm.200305-640OC","journal-title":"Am J Respir Crit Care Med"},{"key":"4906_CR20","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1378\/chest.130.4.1082","volume":"130","author":"R Hubbard","year":"2006","unstructured":"Hubbard R, Tattersfield A, Smith C, West J, Smeeth L, Fletcher A (2006) Use of inhaled corticosteroids and the risk of fracture. Chest 130:1082\u20131088. \n                    https:\/\/doi.org\/10.1378\/chest.130.4.1082","journal-title":"Chest"},{"key":"4906_CR21","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.1210\/jc.2002-020970","volume":"87","author":"S Diederich","year":"2002","unstructured":"Diederich S, Eigendorff E, Burkhardt P, Quinkler M, Bumke-Vogt C, Rochel M, Seidelmann D, Esperling P, Oelkers W, B\u00e4hr V (2002) 11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 87:5695\u20135701. \n                    https:\/\/doi.org\/10.1210\/jc.2002-020970","journal-title":"J Clin Endocrinol Metab"},{"key":"4906_CR22","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.1128\/MCB.16.8.4128","volume":"16","author":"Z Wu","year":"1996","unstructured":"Wu Z, Bucher NL, Farmer SR (1996) Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C\/EBPbeta, C\/EBPdelta, and glucocorticoids. Mol Cell Biol 16:4128\u20134136. \n                    https:\/\/doi.org\/10.1128\/MCB.16.8.4128","journal-title":"Mol Cell Biol"},{"key":"4906_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.bbrc.2005.01.117","volume":"329","author":"K Ohnaka","year":"2005","unstructured":"Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R (2005) Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329:177\u2013181. \n                    https:\/\/doi.org\/10.1016\/j.bbrc.2005.01.117","journal-title":"Biochem Biophys Res Commun"},{"key":"4906_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.bbrc.2008.12.035","volume":"379","author":"K Hayashi","year":"2009","unstructured":"Hayashi K, Yamaguchi T, Yano S, Kanazawa I, Yamauchi M, Yamamoto M, Sugimoto T (2009) BMP\/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 379:261\u2013266. \n                    https:\/\/doi.org\/10.1016\/j.bbrc.2008.12.035","journal-title":"Biochem Biophys Res Commun"},{"key":"4906_CR25","doi-asserted-by":"publisher","first-page":"44326","DOI":"10.1074\/jbc.M111.283481","volume":"286","author":"M Almeida","year":"2011","unstructured":"Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC (2011) Glucocorticoids and tumor necrosis factor \u03b1 increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem 286:44326\u201344335. \n                    https:\/\/doi.org\/10.1074\/jbc.M111.283481","journal-title":"J Biol Chem"},{"key":"4906_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s12020-016-1146-8","volume":"54","author":"G Mazziotti","year":"2016","unstructured":"Mazziotti G, Formenti AM, Adler RA, Bilezikian JP, Grossman A, Sbardella E, Minisola S, Giustina A (2016) Glucocorticoid-induced osteoporosis: pathophysiological role of GH\/IGF-I and PTH\/VITAMIN D axes, treatment options and guidelines. Endocrine 54:603\u2013611. \n                    https:\/\/doi.org\/10.1007\/s12020-016-1146-8","journal-title":"Endocrine"},{"key":"4906_CR27","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1172\/JCI200316069","volume":"111","author":"CT Ritchlin","year":"2003","unstructured":"Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM (2003) Mechanisms of TNF-\u03b1\u2013 and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Investig 111:821\u2013831. \n                    https:\/\/doi.org\/10.1172\/JCI16069","journal-title":"J Clin Investig"},{"key":"4906_CR28","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1530\/eje.1.02147","volume":"154","author":"A Dovio","year":"2006","unstructured":"Dovio A, Perazzolo L, Saba L, Termine A, Capobianco M, Bertolotto A, Angeli A (2006) High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. Eur J Endocrinol 154:745\u2013751. \n                    https:\/\/doi.org\/10.1530\/eje.1.02147","journal-title":"Eur J Endocrinol"},{"key":"4906_CR29","doi-asserted-by":"publisher","first-page":"44667","DOI":"10.1074\/jbc.M300213200","volume":"278","author":"A Takuma","year":"2003","unstructured":"Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y (2003) Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J Biol Chem 278:44667\u201344674. \n                    https:\/\/doi.org\/10.1074\/jbc.M300213200","journal-title":"J Biol Chem"},{"key":"4906_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1474-9726.2009.00545.x","volume":"9","author":"RS Weinstein","year":"2010","unstructured":"Weinstein RS, Wan C, Liu Q, Wang Y, Almeida M, O\u2019Brien CA, Thostenson J, Roberson PK, Boskey AL, Clemens TL, Manolagas SC (2010) Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell 9:147\u2013161. \n                    https:\/\/doi.org\/10.1111\/j.1474-9726.2009.00545.x","journal-title":"Aging Cell"},{"key":"4906_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/jbmr.5650110516","volume":"11","author":"D Chappard","year":"1996","unstructured":"Chappard D, Legrand E, Basle MF et al (1996) Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 11:676\u2013685. \n                    https:\/\/doi.org\/10.1002\/jbmr.5650110516","journal-title":"J Bone Miner Res"},{"key":"4906_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1359\/jbmr.2001.16.1.97","volume":"16","author":"L Dalle Carbonare","year":"2001","unstructured":"Dalle Carbonare L, Arlot ME, Chavassieux PM et al (2001) Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16:97\u2013103. \n                    https:\/\/doi.org\/10.1359\/jbmr.2001.16.1.97","journal-title":"J Bone Miner Res"},{"key":"4906_CR33","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1002\/art.11283","volume":"48","author":"TP Staa Van","year":"2003","unstructured":"Van Staa TP, Laan RF, Barton IP et al (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224\u20133229. \n                    https:\/\/doi.org\/10.1002\/art.11283","journal-title":"Arthritis Rheum"},{"key":"4906_CR34","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1210\/en.2016-1779","volume":"158","author":"AY Sato","year":"2017","unstructured":"Sato AY, Richardson D, Cregor M, Davis HM, Au ED, McAndrews K, Zimmers TA, Organ JM, Peacock M, Plotkin LI, Bellido T (2017) Glucocorticoids induce bone and muscle atrophy by tissue-specific mechanisms upstream of E3 ubiquitin ligases. Endocrinology 158:664\u2013677. \n                    https:\/\/doi.org\/10.1210\/en.2016-1779","journal-title":"Endocrinology"},{"key":"4906_CR35","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1210\/jcem.83.3.4621","volume":"83","author":"G Pearce","year":"1998","unstructured":"Pearce G, Tabensky DA, Delmas PD, Baker HWG, Seeman E (1998) Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 83:801\u2013806. \n                    https:\/\/doi.org\/10.1210\/jcem.83.3.4621","journal-title":"J Clin Endocrinol Metab"},{"key":"4906_CR36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00198-003-1570-5","volume":"15","author":"F Richy","year":"2004","unstructured":"Richy F, Ethgen O, Bruyere O, Reginster J-Y (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301\u2013310. \n                    https:\/\/doi.org\/10.1007\/s00198-003-1570-5","journal-title":"Osteoporos Int"},{"key":"4906_CR37","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00198-004-1614-5","volume":"15","author":"RNJ Nijs de","year":"2004","unstructured":"de Nijs RNJ, Jacobs JWG, Algra A, Lems WF, Bijlsma JWJ (2004) Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15:589\u2013602. \n                    https:\/\/doi.org\/10.1007\/s00198-004-1614-5","journal-title":"Osteoporos Int"},{"key":"4906_CR38","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG, Lane N, Correa-Rotter R, Yanover M, Westhovens R, Epstein S, Adachi JD, Poubelle P, Melo-Gomes J, Rodriguez-Portales JA (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med 339:292\u2013299. \n                    https:\/\/doi.org\/10.1056\/NEJM199807303390502","journal-title":"N Engl J Med"},{"key":"4906_CR39","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Mar\u00edn F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028\u20132039. \n                    https:\/\/doi.org\/10.1056\/NEJMoa071408","journal-title":"N Engl J Med"},{"key":"4906_CR40","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","volume":"15","author":"DM Reid","year":"2000","unstructured":"Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006\u20131013. \n                    https:\/\/doi.org\/10.1359\/jbmr.2000.15.6.1006","journal-title":"J Bone Miner Res"},{"key":"4906_CR41","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","volume":"42","author":"S Cohen","year":"1999","unstructured":"Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309\u20132318. \n                    https:\/\/doi.org\/10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","journal-title":"Arthritis Rheum"},{"key":"4906_CR42","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"JD Adachi","year":"2001","unstructured":"Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PEE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MOR, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202\u2013211. \n                    https:\/\/doi.org\/10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","journal-title":"Arthritis Rheum"},{"key":"4906_CR43","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3899\/jrheum.081207","volume":"36","author":"SA Stoch","year":"2009","unstructured":"Stoch SA, Saag KG, Greenwald M et al (2009) Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36:1705\u20131714. \n                    https:\/\/doi.org\/10.3899\/jrheum.081207","journal-title":"J Rheumatol"},{"key":"4906_CR44","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00223-001-1060-8","volume":"69","author":"DM Reid","year":"2001","unstructured":"Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69:242\u2013247. \n                    https:\/\/doi.org\/10.1007\/s00223-001-1060-8","journal-title":"Calcif Tissue Int"},{"key":"4906_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"S Wallach","year":"2000","unstructured":"Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277\u2013285. \n                    https:\/\/doi.org\/10.1007\/s002230001146","journal-title":"Calcif Tissue Int"},{"key":"4906_CR46","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","volume":"14","author":"JD Ringe","year":"2003","unstructured":"Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F (2003) Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 14:801\u2013807. \n                    https:\/\/doi.org\/10.1007\/s00198-003-1425-0","journal-title":"Osteoporos Int"},{"key":"4906_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.clinthera.2017.01.008","volume":"39","author":"K Shin","year":"2017","unstructured":"Shin K, Park S-H, Park W et al (2017) Monthly oral ibandronate reduces bone loss in Korean women with rheumatoid arthritis and osteopenia receiving long-term glucocorticoids: a 48-week double-blinded randomized placebo-controlled investigator-initiated trial. Clin Ther 39:268\u2013278.e2. \n                    https:\/\/doi.org\/10.1016\/j.clinthera.2017.01.008","journal-title":"Clin Ther"},{"key":"4906_CR48","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1359\/jbmr.090216","volume":"24","author":"A Fahrleitner-Pammer","year":"2009","unstructured":"Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, Obermayer-Pietsch BM, Pilz S, Dimai HP, Prenner G, Tscheliessnigg KH, Hauge E, Portugaller RH, Dobnig H (2009) Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 24:1335\u20131344. \n                    https:\/\/doi.org\/10.1359\/jbmr.090216","journal-title":"J Bone Miner Res"},{"key":"4906_CR49","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer J-P, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253\u20131263. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(09)60250-6","journal-title":"Lancet"},{"key":"4906_CR50","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2017.8040","volume":"318","author":"KF Axelsson","year":"2017","unstructured":"Axelsson KF, Nilsson AG, Wedel H, Lundh D, Lorentzon M (2017) Association between alendronate use and hip fracture risk in older patients using oral prednisolone. JAMA 318:146\u2013155. \n                    https:\/\/doi.org\/10.1001\/jama.2017.8040","journal-title":"JAMA"},{"key":"4906_CR51","doi-asserted-by":"publisher","first-page":"CD001347","DOI":"10.1002\/14651858.CD001347.pub2","volume":"10","author":"CS Allen","year":"2016","unstructured":"Allen CS, Yeung JH, Vandermeer B, Homik J (2016) Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev 10:CD001347. \n                    https:\/\/doi.org\/10.1002\/14651858.CD001347.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4906_CR52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, al Dabagh R, Davison KS, Kendler DL, S\u00e1ndor GK, Josse RG, Bhandari M, el Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, on behalf of the International Task Force on Osteonecrosis of the Jaw (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3\u201323. \n                    https:\/\/doi.org\/10.1002\/jbmr.2405","journal-title":"J Bone Miner Res"},{"key":"4906_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MCH, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1\u201323. \n                    https:\/\/doi.org\/10.1002\/jbmr.1998","journal-title":"J Bone Miner Res"},{"key":"4906_CR54","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1007\/s00198-017-4169-y","volume":"28","author":"JH Koh","year":"2017","unstructured":"Koh JH, Myong JP, Yoo J, Lim YW, Lee J, Kwok SK, Park SH, Ju JH (2017) Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years\u2019 experience in a single center. Osteoporos Int 28:3251\u20133259. \n                    https:\/\/doi.org\/10.1007\/s00198-017-4169-y","journal-title":"Osteoporos Int"},{"key":"4906_CR55","doi-asserted-by":"publisher","first-page":"e016788","DOI":"10.1136\/bmjopen-2017-016788","volume":"7","author":"DB Horton","year":"2017","unstructured":"Horton DB, Haynes K, Denburg MR, Thacker MM, Rose CD, Putt ME, Leonard MB, Strom BL (2017) Oral glucocorticoid use and osteonecrosis in children and adults with chronic inflammatory diseases: a population-based cohort study. BMJ Open 7:e016788. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2017-016788","journal-title":"BMJ Open"},{"key":"4906_CR56","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","volume":"6","author":"KG Saag","year":"2018","unstructured":"Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6:445\u2013454. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(18)30075-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4906_CR57","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32:1291\u20131296. \n                    https:\/\/doi.org\/10.1002\/jbmr.3110","journal-title":"J Bone Miner Res"},{"key":"4906_CR58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gua\u00f1abens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317. \n                    https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"key":"4906_CR59","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.bone.2006.01.142","volume":"39","author":"H Oxlund","year":"2006","unstructured":"Oxlund H, Ortoft G, Thomsen JS et al (2006) The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 39:244\u2013252. \n                    https:\/\/doi.org\/10.1016\/j.bone.2006.01.142","journal-title":"Bone"},{"key":"4906_CR60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3899\/jrheum.090411","volume":"37","author":"J-P Devogelaer","year":"2010","unstructured":"Devogelaer J-P, Adler RA, Recknor C et al (2010) Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol 37:141\u2013148. \n                    https:\/\/doi.org\/10.3899\/jrheum.090411","journal-title":"J Rheumatol"},{"key":"4906_CR61","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/art.39726","volume":"68","author":"KG Saag","year":"2016","unstructured":"Saag KG, Agnusdei D, Hans D et al (2016) Trabecular bone score in patients with chronic glucocorticoid therapy-induced osteoporosis treated with alendronate or teriparatide. Arthritis Rheumatol 68:2122\u20132128. \n                    https:\/\/doi.org\/10.1002\/art.39726","journal-title":"Arthritis Rheumatol"},{"key":"4906_CR62","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00198-009-0917-y","volume":"20","author":"BL Langdahl","year":"2009","unstructured":"Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR (2009) Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 20:2095\u20132104. \n                    https:\/\/doi.org\/10.1007\/s00198-009-0917-y","journal-title":"Osteoporos Int"},{"key":"4906_CR63","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellstr\u00f6m D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441. \n                    https:\/\/doi.org\/10.1056\/NEJM200105103441904","journal-title":"N Engl J Med"},{"key":"4906_CR64","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"Saag KG, Zanchetta JR, Devogelaer J-P, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346\u20133355. \n                    https:\/\/doi.org\/10.1002\/art.24879","journal-title":"Arthritis Rheum"},{"key":"4906_CR65","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jbmr.1870","volume":"28","author":"C-C Gl\u00fcer","year":"2013","unstructured":"Gl\u00fcer C-C, Marin F, Ringe JD, Hawkins F, M\u00f6ricke R, Papaioannu N, Farahmand P, Minisola S, Mart\u00ednez G, Nolla JM, Niedhart C, Gua\u00f1abens N, Nuti R, Mart\u00edn-Mola E, Thomasius F, Kapetanos G, Pe\u00f1a J, Graeff C, Petto H, Sanz B, Reisinger A, Zysset PK (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 28:1355\u20131368. \n                    https:\/\/doi.org\/10.1002\/jbmr.1870","journal-title":"J Bone Miner Res"},{"key":"4906_CR66","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/ard.2010.143453","volume":"70","author":"CC Mok","year":"2011","unstructured":"Mok CC, Ying KY, To CH et al (2011) Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis 70:778\u2013784. \n                    https:\/\/doi.org\/10.1136\/ard.2010.143453","journal-title":"Ann Rheum Dis"},{"key":"4906_CR67","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/rheumatology\/38.12.1239","volume":"38","author":"AW Kung","year":"1999","unstructured":"Kung AW, Chan TM, Lau CS et al (1999) Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy. Rheumatology (Oxford) 38:1239\u20131244. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/38.12.1239","journal-title":"Rheumatology (Oxford)"},{"key":"4906_CR68","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/art.1780371014","volume":"37","author":"GM Hall","year":"1994","unstructured":"Hall GM, Daniels M, Doyle DV, Spector TD (1994) Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 37:1499\u20131505. \n                    https:\/\/doi.org\/10.1002\/art.1780371014","journal-title":"Arthritis Rheum"},{"key":"4906_CR69","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI3914","volume":"102","author":"NE Lane","year":"1998","unstructured":"Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical. trial J Clin Invest 102:1627\u20131633. \n                    https:\/\/doi.org\/10.1172\/JCI3914","journal-title":"trial J Clin Invest"},{"key":"4906_CR70","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial. JAMA 288:321\u2013333. \n                    https:\/\/doi.org\/10.1001\/jama.288.3.321","journal-title":"JAMA"},{"key":"4906_CR71","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/rheumatology\/35.6.568","volume":"35","author":"GM Hall","year":"1996","unstructured":"Hall GM, Larbre JP, Spector TD et al (1996) A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br J Rheumatol 35:568\u2013573. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/35.6.568","journal-title":"Br J Rheumatol"},{"key":"4906_CR72","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/archinte.1996.00440100065008","volume":"156","author":"IR Reid","year":"1996","unstructured":"Reid IR, Wattie DJ, Evans MC, Stapleton JP (1996) Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 156:1173\u20131177. \n                    https:\/\/doi.org\/10.1001\/archinte.156.11.1173","journal-title":"Arch Intern Med"},{"key":"4906_CR73","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1210\/jc.2002-021827","volume":"88","author":"BAL Crawford","year":"2003","unstructured":"Crawford BAL, Liu PY, Kean MT, Bleasel JF, Handelsman DJ (2003) Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 88:3167\u20133176. \n                    https:\/\/doi.org\/10.1210\/jc.2002-021827","journal-title":"J Clin Endocrinol Metab"},{"key":"4906_CR74","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1210\/jcem.85.8.6731","volume":"85","author":"PJ Snyder","year":"2000","unstructured":"Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85:2670\u20132677. \n                    https:\/\/doi.org\/10.1210\/jcem.85.8.6731","journal-title":"J Clin Endocrinol Metab"},{"key":"4906_CR75","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s00198-015-3200-4","volume":"26","author":"JM Albaum","year":"2015","unstructured":"Albaum JM, L\u00e9vesque LE, Gershon AS, Liu G, Cadarette SM (2015) Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996-2012. Osteoporos Int 26:2845\u20132852. \n                    https:\/\/doi.org\/10.1007\/s00198-015-3200-4","journal-title":"Osteoporos Int"},{"key":"4906_CR76","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/rheumatology\/kes079","volume":"51","author":"E McKeown","year":"2012","unstructured":"McKeown E, Bykerk VP, De Leon F et al (2012) Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatology (Oxford) 51:1662\u20131669. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kes079","journal-title":"Rheumatology (Oxford)"},{"key":"4906_CR77","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s00198-009-1114-8","volume":"21","author":"T Beukelman","year":"2010","unstructured":"Beukelman T, Saag KG, Curtis JR, Kilgore ML, Pisu M (2010) Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. Osteoporos Int 21:1573\u20131584. \n                    https:\/\/doi.org\/10.1007\/s00198-009-1114-8","journal-title":"Osteoporos Int"},{"key":"4906_CR78","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/rheumatology\/kel249","volume":"46","author":"TP Staa van","year":"2007","unstructured":"van Staa TP, Geusens P, Zhang B, Leufkens HGM, Boonen A, Cooper C (2007) Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. Rheumatology (Oxford) 46:460\u2013466. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kel249","journal-title":"Rheumatology (Oxford)"},{"key":"4906_CR79","doi-asserted-by":"publisher","unstructured":"Moriwaki K, Fukuda H (2019) Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan. Osteoporos Int. \n                    https:\/\/doi.org\/10.1007\/s00198-018-4798-9","DOI":"10.1007\/s00198-018-4798-9"},{"key":"4906_CR80","first-page":"561","volume":"28","author":"S Adami","year":"2010","unstructured":"Adami S, Bianchi G, Brandi ML et al (2010) Validation and further development of the WHO 10-year fracture risk assessment tool in Italian postmenopausal women: project rationale and description. Clin Exp Rheumatol 28:561\u2013570","journal-title":"Clin Exp Rheumatol"},{"key":"4906_CR81","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385\u2013397. \n                    https:\/\/doi.org\/10.1007\/s00198-007-0543-5","journal-title":"Osteoporos Int"},{"key":"4906_CR82","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809\u2013816. \n                    https:\/\/doi.org\/10.1007\/s00198-010-1524-7","journal-title":"Osteoporos Int"},{"key":"4906_CR83","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/art.40137","volume":"69","author":"L Buckley","year":"2017","unstructured":"Buckley L, Guyatt G, Fink HA et al (2017) 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumat 69:1521\u20131537. \n                    https:\/\/doi.org\/10.1002\/art.40137","journal-title":"Arthritis Rheumat"},{"key":"4906_CR84","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1210\/jc.2014-2177","volume":"99","author":"S Sutter","year":"2014","unstructured":"Sutter S, Nishiyama KK, Kepley A, Zhou B, Wang J, McMahon DJ, Guo XE, Stein EM (2014) Abnormalities in cortical bone, trabecular plates, and stiffness in postmenopausal women treated with glucocorticoids. J Clin Endocrinol Metab 99:4231\u20134240. \n                    https:\/\/doi.org\/10.1210\/jc.2014-2177","journal-title":"J Clin Endocrinol Metab"},{"key":"4906_CR85","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00198-012-2177-5","volume":"24","author":"XL Tang","year":"2013","unstructured":"Tang XL, Qin L, Kwok AW, Zhu TY, Kun EW, Hung VW, Griffith JF, Leung PC, Li EK, Tam LS (2013) Alterations of bone geometry, density, microarchitecture, and biomechanical properties in systemic lupus erythematosus on long-term glucocorticoid: a case-control study using HR-pQCT. Osteoporos Int 24:1817\u20131826. \n                    https:\/\/doi.org\/10.1007\/s00198-012-2177-5","journal-title":"Osteoporos Int"},{"key":"4906_CR86","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/jbmr.2497","volume":"30","author":"L Mellibovsky","year":"2015","unstructured":"Mellibovsky L, Prieto-Alhambra D, Mellibovsky F, G\u00fcerri-Fern\u00e1ndez R, Nogu\u00e9s X, Randall C, Hansma PK, D\u00edez-Perez A (2015) Bone tissue properties measurement by reference point indentation in glucocorticoid-induced osteoporosis. J Bone Miner Res 30:1651\u20131656. \n                    https:\/\/doi.org\/10.1002\/jbmr.2497","journal-title":"J Bone Miner Res"},{"key":"4906_CR87","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43. \n                    https:\/\/doi.org\/10.1007\/s11657-017-0324-5","journal-title":"Arch Osteoporos"},{"key":"4906_CR88","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1136\/ard.2003.008060","volume":"63","author":"PP Geusens","year":"2004","unstructured":"Geusens PP, de Nijs RNJ, Lems WF et al (2004) Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 63:324\u2013325. \n                    https:\/\/doi.org\/10.1136\/ard.2003.008060","journal-title":"Ann Rheum Dis"},{"key":"4906_CR89","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jbspin.2014.10.001","volume":"81","author":"K Briot","year":"2014","unstructured":"Briot K, Cortet B, Roux C, Fardet L, Abitbol V, Bacchetta J, Buchon D, Debiais F, Guggenbuhl P, Laroche M, Legrand E, Lespessailles E, Marcelli C, Weryha G, Thomas T, Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO) (2014) 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine 81:493\u2013501. \n                    https:\/\/doi.org\/10.1016\/j.jbspin.2014.10.001","journal-title":"Joint Bone Spine"},{"key":"4906_CR90","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00198-005-2032-z","volume":"17","author":"J-P Devogelaer","year":"2006","unstructured":"Devogelaer J-P, Goemaere S, Boonen S, Body JJ, Kaufman JM, Reginster JY, Rozenberg S, Boutsen Y (2006) Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17:8\u201319. \n                    https:\/\/doi.org\/10.1007\/s00198-005-2032-z","journal-title":"Osteoporos Int"},{"key":"4906_CR91","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","volume":"32","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, Ozono K, Sagawa A, Takayanagi R, Tanaka H, Miki T, Masunari N, Tanaka Y (2014) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 32:337\u2013350. \n                    https:\/\/doi.org\/10.1007\/s00774-014-0586-6","journal-title":"J Bone Miner Metab"},{"key":"4906_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/reumatismo.2016.870","volume":"68","author":"M Rossini","year":"2016","unstructured":"Rossini M, Adami S, Bertoldo F, Diacinti D, Gatti D, Giannini S, Giusti A, Malavolta N, Minisola S, Osella G, Pedrazzoni M, Sinigaglia L, Viapiana O, Isaia GC (2016) Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 68:1\u201339. \n                    https:\/\/doi.org\/10.4081\/reumatismo.2016.870","journal-title":"Reumatismo"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-019-04906-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-04906-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-04906-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T19:19:09Z","timestamp":1582571949000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-019-04906-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,25]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4906"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-04906-x","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,25]]},"assertion":[{"value":"9 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Giovanni Adami declares that he has no conflict of interest. Kenneth G Saag declares research grant from Amgen and Merck and consultant fee from Amgen, Lilly, Merck, and Radius.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}